Increased production of amyloid ␤ (A␤) 4 peptides and accumulation of A␤ plaques are key hallmarks of Alzheimer disease (AD) pathogenesis. A␤ peptides are considered major mediators of the development of brain lesions characteristic of AD (1-3). The 40-or 42-residue peptides (A␤ 40 and A␤ 42 ) are generated by sequential proteolysis of the amyloid precursor protein (APP) catalyzed by ␤-secretase, ␤-site APP cleaving enzyme I, and presenilin-dependent ␥-secretase (1-3). Progressive accumulation of A␤ peptides enhances fibrillogenic assembly and formation of A␤ load burdens exerting toxic and disruptive effects on neurons, synaptic plasticity, and cognitive functions (1, 4, 5) . Reducing the accumulation of A␤ deposition is thus believed to be a useful therapeutic strategy (6) , and extensive research has aimed at understanding the processes governing APP proteolysis, A␤ stability, and A␤ clearance.
Glycogen synthase kinase-3 (GSK-3) is an evolutionary conserved serine/threonine kinase expressed as two isozymes: GSK-3␣ and GSK-3␤ (7) . Hyperactive GSK-3 has been implicated in the etiology of neurodegenerative diseases including Parkinson disease, amyotrophic lateral sclerosis, AD, and brain aging (8 -12) . Aberrant phosphorylation of AD-related compo-nents such as microtubule-associated protein Tau, presenilins, collapsin response mediator proteins, and ␤-catenin by GSK-3 underlie mechanisms contributing to pathogenesis (8 -11) , and thus inhibition of GSK-3 should be an effective therapeutic strategy (13) .
The contribution of GSK-3 to A␤ neuropathology has been disputed, however. Initially, it was shown that GSK-3␣ enhanced ␥-secretase-mediated A␤ peptide production in CHO cells overexpressing APP (14) . A recent report challenged these results and showed that knock-out of GSK-3␣ or GSK-3␤ in the mouse brain did not alter levels of APP metabolites or A␤ peptides (15) . Other studies showed that treatment with GSK-3 inhibitors, lithium, or NP12 or silencing of GSK-3␣ with hairpin RNA constructs reduced A␤ deposition in various AD mouse models (14, 16, 17 ), yet our understanding of mechanisms behind GSK-3 regulation of A␤ pathology is limited.
The mammalian target of rapamycin (mTOR) is a major nutrient-sensing component that integrates input from growth factors and nutrients to control cell growth (18 -20) . Abnormal activation of the mTOR signaling pathway has been implicated in A␤ pathology and behavior dysfunctions (21, 22) . Recent studies indicate a tight link between mTOR and the lysosomal system in regulating cellular responses to multiple nutrient cues (23, 24) . Lysosomes are acidic organelles responsible for cellular degradation (25) , and malfunction of lysosomes is causative in AD pathogenesis (26 -28) . Although GSK-3 may be involved in activation of mTOR (29, 30) , the molecular interplay between GSK-3, lysosomal regulation, and mTOR is unknown. Nor is it known whether the GSK-3/mTOR/lysosomal axis contributes to AD pathogenesis.
To gain further insights into the role of GSK-3 in A␤ pathology, we used 5XFAD mice. These mice co-express a total of five familial AD mutations in APP and presenilin-1 (PS1) and develop massive cerebral A␤ 42 loads, memory deficits, and neuron loss at an early age (31) . We treated the mice nasally with L803-mts, a selective, substrate-competitive inhibitor of GSK-3 that was previously characterized in diverse biological systems (32) (33) (34) (35) (36) (37) . Treatment with L803-mts reduced A␤ pathology and ameliorated cognitive deficits in the 5XFAD mice. By analyses of 5XFAD brains and cell-based systems, we uncovered a novel role for GSK-3 in regulating lysosomal acidification. Our data suggest that restoration of lysosomal acidification and mTOR activity is the molecular basis of the reversal in AD symptoms achieved with GSK-3 inhibition.
EXPERIMENTAL PROCEDURES
Materials-L803-mts peptide was synthesized by Genemed Synthesis, Inc. AR-A014418, SB-216763, and 6-Bio were purchased from Sigma. Antibodies against phospho-GSK-3␣/␤, phopsho-S6K-1 (Thr-389), S6K-1, phospho-S6 (Ser-240/244), S6 protein, phospho-eukaryotic elongation factor 2 (eEF2; Thr-56), eEF2, and LC3I/II were from Cell Signaling Technologies. Antibodies against GSK-3␣/␤, ␤-actin, v-ATPase V0A1, cathepsin D, Lamp1, and Lamp2 were from Santa Cruz Biotechnology, and anti-mTOR was from Abcam. Anti-p62/ SQSTM was from MBL. Anti-␤-catenin was from Transduction Laboratories, and anti-␤-amyloid, 1-16 (6E10) was purchased from Covance.
Animals and Behavior Tests-We used 5XFAD transgenic mice (Tg6799) that co-overexpress FAD mutant forms of human APP (the Swedish mutation, K670N/M671L; the Florida mutation, I716V; and the London mutation, V717I) and PS1 (M146L/L286V) transgenes under transcriptional control of the neuron-specific mouse Thy-1 promoter (31) . Hemizygous transgenic mice were crossed with C57Bl/6J breeders. Genotyping was performed by PCR analysis of tail DNA as described (31) . The mice were housed in individual cages in a temperature-controlled facility with a 12-h light/dark cycle. 5XFAD mice were randomly assigned to two groups (six animals each). Treatment started at the age of 2 months, and L803-mts (80 g total in vehicle solution, 128 mM NaCl, 8 mM citric acid monohydrate, 17 mM disodium phosphate dehydrate, and 0.0005% benzalkonium chloride) was administered intranasally (5 l of solution in each nostril) every other day for 120 days. The contextual fear conditioning test was conducted as described (38) . Briefly, mice were subjected to an unconditioned electric stimulus (one foot shock; 1 s/1 mA) in a training presession. 24 h later, a fear conditioning test was performed by scoring freezing behavior, e.g., the absence of all but respiratory movement for 180 s using a FreezeFrame automated scoring system (Coulbourn Instruments). All experiments were in compliance with protocols approved by the Tel Aviv University animal care committee.
Histology and A␤ Staining-Saline-perfused brains were rapidly excised and frozen in N 2 . The brains were divided into the two hemispheres: the left hemisphere was taken for immunohistology, and the right hemisphere was taken for immunoblot analysis. Coronal brains sections (14 m) were cut by cryostat at Ϫ20°C. Slices at Bregma Ϫ1.58 mm were fixed (4% paraformaldehyde) and stained with Congo red dye (Sigma-Aldrich) or with an antigen-retrieval method with anti-A␤ 6E10 antibody (SIG-39300) and visualized by fluorescence microscopy. Quantification of A␤ depositions was done for the whole hippocampus area in a blinded fashion using Imaging Research software from the National Institutes of Health in an unbiased stereological approach.
Brain Extracts-Right cerebral hemispheres were homogenized in ice-cold buffer H (150 mM ␤-glycerophosphate, pH 7.3, 10% glycerol, 5 mM EGTA, 5 mM EDTA, 40 mM NaF, 25 mM sodium pyrophosphate, 25 g/ml leupeptin, 25 g/ml aprotinin, 10 g/ml pepstatin A, 1 mM DTT, and 1% Nonidet P-40). The extracts were centrifuged at 14,000 ϫ g for 30 min, and supernatants were collected. Equal amounts of protein (30 -50 g) were subjected to gel electrophoresis followed by immunoblot analysis using the indicated antibodies. Analysis of ␤-actin levels demonstrated equal protein loading.
Cell Culture and Transfection-SH-SY5Y cells were grown in RPMI 1640 medium supplemented with 10% FCS, 5 mM L-glutamine, and 0.04% gentamycin. The cells were maintained in growth medium, in RPMI supplemented with 0.1% or 1.5% FCS, or in a Krebs-Ringer-HEPES buffer (12 mM NaCl, 0. (39) . The cells were grown in DMEM supplemented with 10% FCS, 5 mM L-glutamine, and 1% penicillin-streptomycin. Chinese hamster ovary cells stably expressing human wild-type APP-751 (CHO-APP) were kindly provided by Dr. Denis Selkoe (Harvard Medical School) were grown in DMEM/F-12 medium supplemented with 10% FCS, 2 mM L-glutamine, 0.5 mg/ml L-proline, and 1% penicillin-streptomycin and maintained with antibiotics for G418 selection (1 mg/ml). SHSY-5Y cells were transiently transfected with GFP-GSK-3 constructs (5-7 g) using Lipofectamine 2000 (Invitrogen). For silencing of GSK-3, the cells were transfected with 50 nM GSK-3␣ or GSK-3␤ siRNA or with a scrambled control siRNA (Thermo Scientific/Dharmacon) using the transfection reagent Dharmafect (Thermo Scientific/Dharmacon) according to the manufacturer's instructions. For infections, we used recombinant adenovirus coding for GSK-3␣ or GSK-3␤ (prepared by Z. Liberman in the laboratory) at 1:500 dilution. Adenovirus coding for ␤-gal was used as a control. The cells were harvested 24 h postinfection.
Partial Purification of Lysosomes-The cells were washed with PBS, collected with wash buffer (125 mM KCl, 30 mM Tris, pH 7.5, 5 mM MgOAc, 1 mM ␤-mercaptoethanol), and centrifuged at 800 ϫ g for 5 min. The cells were resuspended in hypotonic buffer (10 mM KCl, 30 mM Tris, pH 7.5, 5 mM MgOAc, 1 mM ␤-mercaptoethanol, and protease inhibitors aprotenin, leupeptine, and pepstatin A) and broken by 30 piston strokes. Homogenates were centrifuged at 1000 ϫ g to precipitate nuclei. The supernatants were collected and centrifuged at 100,000 ϫ g for 1 h at 4°C. The particulate membrane fraction that included lysosomes was boiled with SDS sample buffer and subjected to immunoblot analysis. Detection of Lamp1 in the pellet and not in the supernatant confirmed the presence of lysosomes in this fraction.
Gel Electrophoresis and Immunoblotting-The cells were collected and lysed in an ice-cold buffer G (20 mM Tris-HCl, 10% glycerol, 1 mM EDTA, 1 mM EGTA, 0.5% Triton X-100, 0.5 mM orthovanadate, 10 mM ␤-glycerophosphate, 5 mM sodium pyrophosphate, 50 mM NaF, 1 mM benzaminidine, and protease inhibitors aprotenin, leupeptine, and pepstatin A). Cell extracts were centrifuged at 14,000 ϫ g for 20 min, and supernatants were collected. Equal amounts of protein (40 g) were subjected to gel electrophoresis and Western blot analysis using indicated antibodies. Analysis of ␤-actin levels demonstrated equal protein loading.
Live Cell Imaging-The cells were treated as indicated and incubated with 75 nM LysoTracker Red (Molecular Probes) for 30 min at 37°C. Live cell imaging was taken using a 63.0 ϫ 1.40 oil UV objective lens on a laser scanning confocal microscope (Leica TCS-SP5 II) with spatial resolution of 50 -70 nm. Z-projection images were collected, and stacked images (23 stacks) were generated using LAS-AF Lite software.
Statistical Analysis-Data comparisons were performed using the Student's t test when two groups were compared or one-way analysis of variance when three or more groups were analyzed.
RESULTS

L803-mts Treatment Reduces A␤ Deposits and Ameliorates
Cognitive Deficits in 5XFAD Mice-We first compared GSK-3 levels in hemi-brain blots prepared from 5XFAD mice and agematched C57Bl/6J mice of similar genetic background (referred to here as wild type (WT)). GSK-3␣ and GSK-3␤ protein levels were comparable in WT and 5XFAD mice; however, phosphorylation levels on serine inhibitory sites (Ser-21 on GSK-3␣ and Ser-9 on GSK-3␤) were markedly lower in the 5XFAD brains than in WT brains (Fig. 1A) , indicating that both GSK-3 isozymes are hyperactive in the 5XFAD brain.
The 5XFAD mice begin to develop amyloid plaque burdens at 2 months of age (31) . Therefore, L803-mts treatment was begun at 2 months of age, and the compound was given nasally for 120 days. We chose the nasal route because this has previously been demonstrated to be an effective drug delivery route to the central nervous system (40, 41) . Increased levels in brain ␤-catenin served as an in vivo marker for inhibition of GSK-3 by L803-mts (Fig. 1B) , because GSK-3 activity destabilizes ␤-catenin (42, 43) . Interestingly, in untreated mice, ␤-catenin levels were lower in 5XFAD brains than in WT brains (Fig. 1B) , a possible outcome of hyperactive GSK-3 ( Fig. 1A ) and a phenomenon detected in AD patients carrying the PS1 mutation (44) . At 6 months of age, mice were subjected to a contextual fear conditioning test, a behavioral test widely used to evaluate associative learning and memory. As reported previously, untreated 5XFAD mice showed poorer cognitive abilities than WT mice (31, 45) , manifested by reduced freezing duration (20 Ϯ 10% of the time of WT mice; Fig. 1C ). Treatment with L803-mts improved performance to 72 Ϯ 14% of WT mice (Fig.  1C) .
We then analyzed the impact of L803-mts on A␤ loads. Treatment with L803-mts reduced the amount and the mean sizes of A␤ loads by 75 Ϯ 6.8% as evaluated by staining of brain sections with Congo red dye (Fig. 1D , upper panels). This was further confirmed by immunostaining of brain sections with a specific A␤ monoclonal antibody that indicated a reduction in A␤ loads by 84 Ϯ 20% (Fig. 1D, lower panels) . Because intraneuronal A␤ 42 is the primary peptide that accumulates in this model (31) , it appeared that L803-mts treatment significantly reduced levels of this A␤ species. Total APP holoprotein levels were not reduced by L803-mts (Fig. 1E) , suggesting that the effect on A␤ loads is post-translational. Thus, inhibition of GSK-3 by L803-mts attenuated the progressive accumulation of A␤ deposits in the mouse brain and improved cognitive functions.
L803-mts Inhibits Autophagy and Restores mTOR and Lysosomal Activity in the 5XFAD Brain-We next sought to investigate the mechanism of action responsible for reduction in A␤ pathology upon inhibition of GSK-3. Levels of insulin-degrading enzyme, an enzyme that degrades A␤ plaques (46), were not altered by treatment with L803-mts ( Fig. 2A) , nor did we find changes in the expression levels of the chaperone heat shock protein (Hsp70) or defects in the insulin signaling pathway (as demonstrated by phosphorylation of Akt/PKB) ( Fig. 2A) , both implicated in protein aggregate degradation (47) (48) (49) . It should be noted that GSK-3 is phosphorylated by multiple protein kinases other than Akt, including Ca ϩ2 calmodulin-dependent protein kinase II, PKA, and S6 ribosomal proteins kinase p90 RSK (50 -52) . In addition, GSK-3 is dephosphorylated by several different phosphatases (53) . Thus, alterations in GSK-3 phosphorylation observed in the 5XFAD brain (Fig. 1A) could be catalyzed by one or more of these components.
We thus considered mechanisms mediated by the autophagy/lysosomal degradative pathway that recycles macromolecules and organelles (54, 55) . This pathway was recently implicated in APP processing and A␤ clearance (27, 56) . LC3-II, a lipidated form of microtubule-associated protein 1 light chain 3-I (LC3-I), is exclusively associated with autophagosome membranes and serves as a marker for autophagosomes (54, 57, 58) . Levels of LC3-II and the relative ratio of LC3-II to total LC3 (LC3-IϩLC3-II) were similar in 5XFAD and WT brains as determined by immunoblot analysis (Fig. 2B) . Treatment with L803-mts led to a small reduction in LC3-II/LC3 ratio (Fig. 2B) , indicating that L803-mts could inhibit autophagy. To support this possibility, we measured p62/SQSTM, an autophagy substrate whose levels inversely correlate with autophagic activity (59) . Indeed, treatment with L803-mts significantly increased p62/SQSTM levels in the 5XFAD mouse brain (Fig. 2C) , indicating that L803-mts inhibited autophagic activity.
The mTOR is a "classical" autophagy suppressor (54, 60, 61) . We thus sought to determine whether mTOR activity was altered by in L803-mts-treated mice. mTOR activity was evaluated by measuring the phosphorylation levels of the direct mTOR target p70S6 ribosomal kinase (S6K1) and its downstream substrate ribosomal S6 protein (S6). We also determined the phosphorylation levels of eEF2, an essential factor in the protein synthesis machinery and a downstream target of mTOR (62) and GSK-3 (29) . Phosphorylation of eEF-2 on Thr-56 inhibits its activity (62) . Phosphorylation levels of S6K1 and S6 were significantly reduced in 5XFAD brains as compared with WT brains (Fig. 2D) , and treatment with L803-mts enhanced phosphorylation of these proteins in brains of 5XFAD mice (Fig. 2D) . In addition, phosphorylation of eEF-2 was reduced in L803-mts-treated 5XFAD brains, indicating activation of eEF-2 (Fig. 2D) . Together, these data indicated that L803-mts restored mTOR activity, which was inhibited in the 5XFAD mice brain.
We next examined the activity of the lysosomal pathway that may clear aggregated proteins, including A␤ loads, independent of autophagy (26, 28, 63) . Lysosomes are acidic organelles that contain many hydrolytic enzymes (64, 65) . The vacuolar ATPase (v-ATPase) proton pump maintains lysosomal acidification (66, 67) . Cathepsin D (CatD), the principal lysosomal aspartyl protease, is highly abundant in the brain and activated by proteolysis in the acidified lysosome to produce a mature proteolytic product (mCatD) (68) . Precursors CatD (ϳ46 -52 kDa) and mCatD (ϳ32 kDa) were detected in WT, L803-mts treated, and nontreated 5XFAD brains (Fig. 3A) . mCatD levels were lower in the 5XFAD brains than in WT brains, and treatment with L803-mts restored this deficit (Fig. 3A) . These results indicated that lysosomal acidification is impaired in the 5XFAD brains. To further assess lysosomal acidification, we determined the extent of N-glycosylation of the v-ATPase subunit, ATPase V0a1, that facilitates assembly of the proton pump in the lysosome (69, 70) . Immunoblot analysis using anti-vATPase V0a1 antibody revealed a doublet band corresponding to nonglycosylated (100 kDa) and mature glycosylated (120 kDa) v-ATPase V0a1 in brains of all groups (Fig. 3B) . Levels of mature ATPase V0a1 were lower in the 5XFAD brains than in WT brains (Fig. 3B) , and treatment with L803-mts increased mature ATPase V0a1 levels by 2.5-fold (Fig. 3B) . Therefore, one of the effects of GSK-3 inhibition by L803-mts is to restores lysosomal acidification in the 5XFAD brain by facilitating N-glycosylation of v-ATPase V01A.
Role of GSK-3 in Regulating Lysosomal Acidity-We next used a simple cell culture system to validate our in vivo results and to gain further insights into GSK-3 regulation of lysosomes and mTOR. Treatment of "neuron-like" human neuroblastoma SH-SY5Y cells with L803-mts activated lysosomal proteolytic activity as determined by increased levels of mCatD in "total" cell extract (Fig. 4A ) or in partially purified lysosomes (data not shown). Treatment with chloroquine, which neutralizes lysosomal pH, served as a negative control and lowered mCatD (Fig.  4A ). An increase in glycosylated v-ATPase V0a1 (Fig. 4B ) further indicated that L803-mts treatment enhanced lysosomal acidification. Treatment with tunicamycin, which blocks N-linked glycosylation of proteins, abolished the 120-kDa band of v-ATPase V0a1 and verified glycosylation (Fig. 4B) .
We examined changes in lysosomal acidity using LysoTracker Red, a dye that accumulates in acidic organelles. The cells were stained with LysoTracker Red, and live cells were imaged by confocal microscopy. Lysosomes appeared as red punctate in cell images (Fig. 4C) . Treatment with chloroquine reduced the fluorescence of the red vesicles and confirmed dye specificity (Fig. 4C) . A similar observation was obtained after treatment with tunicamycin, verifying the importance of glycosylation in lysosomal acidification (Fig. 4C) . Treatment of cells with L803-mts increased the number of acidified lysosomes and intensity of staining as compared with control untreated cells (Fig. 4C) . These results were consistent with the in vivo data and indicate that L803-mts increased the pool of acidic lysosomes.
To examine whether GSK-3 isozymes have distinct roles in regulating lysosomal acidity (and activity), GSK-3␣ or GSK-3␤ were overexpressed in SH-SY5Y cells using a recombinant adenovirus system. Control cells were infected with ␤-gal adenovirus. Overexpression of either GSK-3␣ or GSK-3␤ markedly reduced mCatD levels (Fig. 5A) . We next evaluated the effect of inhibition of GSK-3 expression using siRNA. Although the reduction in GSK-3␤ expression increased mCatD levels (Fig.  5B) , silencing of GSK-3␣ had no significant effects (Fig. 5B) . It is possible that reductions in GSK-3␣ levels were not sufficient to impact lysosomal acidification or that activity of GSK-3␤ compensated for the reduction in GSK-3␣ activity. The cells were then transfected with GFP-tagged-GSk-3␣ or -GSK-3␤ and were stained with LysoTracker Red. Staining was consistently lower in cells expressing the GSK-3 isozymes as compared with control cells expressing the GFP protein only (Fig. 5C) . Levels of lysosomal Lamp2 were not significantly altered in the GSK-3 overexpressing cells (Fig. 5D) , indicating that GSK-3 did not affect lysosomes number but, rather, altered their acidification. We concluded that both GSK-3 isozymes impair lysosomal acidification. 
mTOR Is Activated by GSK-3 and Inhibited by Impaired Lysosomal Activity or Overexpression of APP-Our in vivo results
indicated that treatment with L803-mts restored mTOR activity in the 5XFAD brain (Fig. 2D) . It may be that hyperactive GSK-3 in the 5XFAD brain (Fig. 1A) is responsible for inhibition in mTOR. We evaluated the regulation of mTOR by GSK-3 in SH-SY5Y cells. Overexpression of GSK-3␣ or GSK-3␤ in these cells activated mTOR as indicated by increased phosphorylation of the mTOR targets S6K1 and S6 (Fig. 6A) . The use of rapamycin, which primarily blocks activity of the mTORC1 complex, suggested that GSK-3 activates mTORC1 (Fig. 6B) . Treatment with diverse GSK-3 inhibitors SB-216763, CT-99012, 6-Bio, and L803-mts verified this conclusion; all inhibitors inhibited the phosphorylation of S6 (Fig. 6C) . Hence, reactivation of mTOR observed in L803-mts-treated 5XFAD mice was likely not a direct consequence of inhibition of GSK-3, nor was hyperactivity of GSK-3 responsible for the inhibition of mTOR detected in 5XFAD brains.
We thus searched for additional elements that could inhibit mTOR in the 5XFAD brain. We examined whether defective lysosomal acidification inhibit mTOR. Indeed, treating cells with chloroquine reduced phosphorylation of S6 (Fig. 6D) . Overexpression of GSK-3␣ or GSK-3␤ prevented (in part) inhibition in mTOR by chloroquine (Fig. 6D) . Hence, GSK-3 activates mTOR independent of lysosomal acidity. We also considered that elevated burdens of APP or A␤ may inhibit mTOR in the 5XFAD brain. We thus examined mTOR activity in Chinese hamster ovary cells stably expressing APP (CHO-APP 751 ). Indeed, phosphorylation levels of mTOR targets were substantially lower in the CHO-APP 751 cells as compared with control CHO cells (Fig. 6E) . Taken together, our data indicate that GSK-3 is a positive regulator of mTOR and suggest that defective lysosomal acidification and high APP/A␤ burdens were responsible for impaired mTOR activity in the 5XFAD brain.
L803-mts Restores Impaired Lysosomal Acidification in Cells Deficient in Presenilins-PS1
is essential for lysosomal acidification (69, 71) . Although our results implicated activation of GSK-3 as a possible mechanism responsible for impaired lysosomal acidification in the 5XFAD brain, we cannot ignore the possibility that dysfunctional PS1 is another factor that disrupts lysosomal activity. It was thus important to evaluate whether L803-mts restored lysosomal acidification caused by defective PS. For this purpose, we used MEF cells deficient in PS1 and PS2 (MEF-PS1/2 Ϫ/Ϫ ) (39). MEF-PS1/2 Ϫ/Ϫ exhibited reduced mature ATPase V0a1, reduced mCatD levels (Fig. 7A) , and less acidified lysosomes than wild-type cells (Fig. 7B) . Treating MEF-PS1/2 Ϫ/Ϫ cells with L803-mts increased the number and intensity of staining of lysosomes (Fig. 7B) . Similar results were obtained in cells treated with different GSK-3 inhibitors, SB-216763 or LiCl (Fig. 7B ). Study in partial purified lysosomes showed that L803-mts increased glycosylated content of ATPase V0a1 and increased mCatD levels but did not alter levels of Lamp1 (Fig. 7C) . These data show that GSK-3 inhibition can compensate for impaired lysosomal acidification caused by dysfunctional PS1/PS2.
DISCUSSION
In this study we showed that inhibition of GSK-3 reduced the burden of A␤ plaques in an aggressive Alzheimer model, the 5XFAD mouse. We provided a proof of therapeutic benefits of nasal administration of the GSK-3 inhibitor, L803-mts, and gained new insight into the mechanisms underlying GSK-3 regulation of A␤ pathology and cognition. Our data show that GSK-3 regulates lysosomal acidification and is an mTOR activator. We suggest that the molecular interplay between the lysosomal and mTOR pathways governed by GSK-3 inhibition is a molecular basis for reduced amyloid ␤ pathology and improved cognition observed in the L803-mts-treated AD mice.
Our study revealed a previously unsuspected link between GSK-3 and the regulation of lysosomal function. Lysosomal acidification was impaired in the 5XFAD brain, and treatment with L803-mts restored acidification. This recovery was mediated at least in part by increased glycosylation of v-ATPase subunit V0a1; this subunit facilitates the "correct" assembly of the v-ATPase proton pump important for lysosomal acidification (69) . Data from in vitro studies using SH-SY5Y cells supported our conclusions. Cellbased studies showed that overexpression of either GSK-3 isozyme impaired lysosomal acidification and that treatment with L803-mts enhanced CatD activity, enhanced glycosylation of V0a1, and increased the pool of acidified lysosomes. Treatment with tunicamycin confirmed the importance of glycosylation in maintaining lysosomal acidification (Fig. 4) . Our results are in line with accumulating evidence demonstrating the importance of the lysosomal system for A␤ clearance and AD pathogenesis. Indeed, lysosome function declines with age (72), and CatD activity was previously shown to be correlated with neuroprotection from degenerative disease (63, 73) . Inhibition of lysosomal activity increased brain A␤ loads that were diminished by enhanced cathepsin activities (27, 74) . In addition, the anti-amyloidogenic role of lysosomal proteolysis has been demonstrated in storage disease models (28) , and enhanced lysosomal activity triggered by a pharmacological activator reduces A␤ pathology and ameliorates behavioral deficits in different AD mouse models (26, 75) . Given the role of lysosomes in amyloidal clearance, it is tempting to suggest that deficits in lysosomal acidification observed in the 5XFAD brain contribute to the rapid and massive accumulation of A␤ loads observed in these mice (31) . Hence, restoration of lysosomal activity by L803-mts was probably responsible, at least in part, for the clearance in A␤ deposits observed in the treated mice. It is important to note that L803-mts had a preventative effect, because treatment was begun prior the appearance of A␤ pathology. Our results corroborate previous studies that showed that inhibition in GSK-3 activity reduced A␤ production and/or A␤ pathology (14, 16, 17) . The one study that showed that knock-out of GSK-3␣ or GSK-3␤ in the mouse brain did not affect APP metabolism or A␤ levels (15) was performed using an in vivo model that lacked A␤ pathology, and the role of GSK-3 might have been masked under these conditions.
An additional important finding of our study is the demonstration of GSK-3 as a "positive regulator" of the mTOR pathway. We previously reported that GSK-3 activated the mTOR target eEF-2 (29) , and another study showed GSK-3 activation of mTOR in cancer cells (29, 30) . Thus, reactivation of mTOR by L803-mts in the 5XFAD brain was not mediated by direct inhibition of GSK-3. Rather, we suggest that disrupted lysosomal activity and elevated APP/A␤ burdens are responsible for inhibition of mTOR in the 5XFAD brain and that normalization of lysosomal activity enabled normalization in mTOR activity. Furthermore, the reduction in A␤ deposits upon GSK-3 inhibition is an additional factor that enables reactivation of mTOR. Previous studies indeed provide a support for a tight link between lysosomal regulation and mTOR (23, 24) , and others have demonstrated inhibition of mTOR by A␤ peptides (76, 77) . It is noteworthy that aberrant regulation of mTOR has been implicated in behavior dysfunctions and memory loss (21, 22) . Reduced mTOR activity was reported in AD patients (77) and was demonstrated in subjects with impaired synaptic plasticity and cognitive functions (76 -78) . On the other hand, activation of mTOR has been shown to improve cognitive deficits and was linked with reduction in A␤ pathology (76, 77) . Hence, reduced mTOR activity in the brains of 5XFAD mice could be well attributed to their cognitive decline, and restoration of mTOR activity by L803-mts repaired (in part) cognitive deficits. Altogether, we suggest that reacidification of lysosomes enhanced A␤ burden clearance and enabled reactivation of mTOR, which, in turn, reversed AD pathogenesis (summarized in Fig. 8) .
Although previous studies indicated a role for autophagy in ␤-amyloid clearance (56, 79), we did not find indications for enhanced autophagy in brains of L803-mts-treated mice. We observed a reduced LC3II/LC3I ratio and increased p62/ SQSTM, indicating that autophagy was suppressed in the L803-mts-treated mouse brain. Reactivation of mTOR, a primary autophagy suppressor (54, 60, 61) , detected in brains of L803-mts-treated mice, was likely responsible for inhibited autophagy. Hence, lysosomal activity enhanced clearance of A␤ loads independent of autophagy. Indeed, autophagy-indepen- , and LiCl (20 mM). The lysosomes were partially purified as described under "Experimental Procedures." Lysosome precipitates were immunoblotted for Lamp1, v-ATPase V0a1, CatD, and mCatD. The faint band corresponding to the 14-kDa mCatD is shown. dent, lysosomal-mediated APP processing and A␤ clearance has been demonstrated previously (26, 28) .
The GSK-3 isozymes did not appear to have different roles in regulation of mTOR or lysosomal acidification. This was not an unexpected observation because GSK-3 isozymes frequently show redundant activity (for example, as in Ref. 80 ). It should be noted, however, that GSK-3␣ was previously implicated in A␤ production (14) and A␤ plaque formation (17) . Thus, it is possible that GSK-3 isozymes influence A␤ pathology by similar and by distinct pathways (14, 16, 81, 82) .
Recent studies showed that PS1 is essential for lysosomal acidification (69, 71, 83) and implicated defects in glycosylation of v-ATPase subunit V0a1 as the cause of impaired lysosomal acidification in PS1-deficient cells (69) . Treatment with L803-mts restored impaired lysosomal acidification in PS1/2-deficient cells, indicating that inhibition of GSK-3 could compensate for impaired lysosomal acidification caused by dysfunctional PS1. This suggested a possible cross-talk between presenilins and GSK-3 signaling that should be further investigated. Like deficits in PS1, hyperactive GSK-3 may contribute to impaired lysosomal acidification detected in the 5XFAD mice brains, and the mechanism that underlies this impairment may be shared.
In summary, we show that GSK-3 contributes to A␤ pathology developed in the AD mouse brain. We suggest that by normalizing lysosomal acidification and reactivation of mTOR, the GSK-3 inhibitor, L803-mts, inhibits accumulation of A␤ burdens and ameliorates cognitive function. GSK-3 thus appears to be a novel drug target for the treatment of AD.
